MEREO BIOPHARMA GROUP PLC Operating Lease, Right-of-Use Asset, Amortization Expense
MEREO BIOPHARMA GROUP PLC (MREO) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $268.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-11
- MEREO BIOPHARMA GROUP PLC operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $134.00K, a 1.47% decline year-over-year.
- MEREO BIOPHARMA GROUP PLC operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $134.00K, a 6.35% increase year-over-year.
- MEREO BIOPHARMA GROUP PLC operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $132.00K, a 4.76% increase year-over-year.
- MEREO BIOPHARMA GROUP PLC operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $133.00K, a 3.10% increase year-over-year.
- MEREO BIOPHARMA GROUP PLC operating lease, right-of-use asset, amortization expense for fiscal 2025 was $527.00K, a 3.94% increase from fiscal 2024.
- MEREO BIOPHARMA GROUP PLC operating lease, right-of-use asset, amortization expense for fiscal 2024 was $507.00K, a 2.42% increase from fiscal 2023.
- MEREO BIOPHARMA GROUP PLC operating lease, right-of-use asset, amortization expense for fiscal 2023 was $495.00K, a 30.08% decline from fiscal 2022.
- MEREO BIOPHARMA GROUP PLC operating lease, right-of-use asset, amortization expense for fiscal 2022 was $708.00K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $134.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $268.00K 10-Q · filed 2026-08-11 | $400.00K derived: sum of 3 quarters · filed 2026-08-11 | $533.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $134.00K 10-Q · filed 2026-05-12 | $266.00K derived: sum of 2 quarters · filed 2026-05-12 | $399.00K derived: sum of 3 quarters · filed 2026-05-12 | $535.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $132.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $265.00K derived: sum of 2 quarters · filed 2026-03-19 | $401.00K derived: sum of 3 quarters · filed 2026-08-11 | $527.00K 10-K · filed 2026-03-19 |
| 2025-09-30 | $133.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $269.00K derived: sum of 2 quarters · filed 2026-08-11 | $395.00K 10-Q · filed 2025-11-10 | $521.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $136.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $262.00K 10-Q · filed 2026-08-11 | $388.00K derived: sum of 3 quarters · filed 2026-08-11 | $517.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $126.00K 10-Q · filed 2026-05-12 | $252.00K derived: sum of 2 quarters · filed 2026-05-12 | $381.00K derived: sum of 3 quarters · filed 2026-05-12 | $507.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $126.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $255.00K derived: sum of 2 quarters · filed 2026-03-19 | $381.00K derived: sum of 3 quarters · filed 2026-03-19 | $507.00K 10-K · filed 2026-03-19 |
| 2024-09-30 | $129.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $255.00K derived: sum of 2 quarters · filed 2025-11-10 | $381.00K 10-Q · filed 2025-11-10 | $505.00K derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $126.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $252.00K 10-Q · filed 2025-08-12 | $376.00K derived: sum of 3 quarters · filed 2025-08-12 | $502.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $126.00K 10-Q · filed 2025-05-13 | $250.00K derived: sum of 2 quarters · filed 2025-05-13 | $376.00K derived: sum of 3 quarters · filed 2025-05-13 | $500.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $124.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $250.00K derived: sum of 2 quarters · filed 2025-03-26 | $374.00K derived: sum of 3 quarters · filed 2025-03-26 | $495.00K 10-K · filed 2025-03-26 |
| 2023-09-30 | $126.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $250.00K derived: sum of 2 quarters · filed 2024-11-12 | $371.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $124.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $245.00K 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $121.00K 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | $708.00K 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |